The US Association for Accessible Medicines has listed six key areas for reform during a competition-focused US Senate Judiciary Committee hearing in order to “ensure that the patent system is appropriately balanced, and that antitrust law is properly used to police truly anticompetitive behavior.”
Maintaining “skinny label” carve-outs of patented indications and prohibiting false and misleading statements about the safety and efficacy of biosimilars...




